CAS 144457-28-3
:CLOPIDOGREL CARBOXYLIC ACID
- (S)-α-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5
- (4H)-acetic Acid
- [(+)-(S)-(o-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetic acid
- (2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetic acid
- (S)-α-(2-Chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetic Acid
- ((S)-Clopidogrel Carboxylic Acid)
- Clopidogrel Related Compound A
- (S)-2-(2-Chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetic acid
- Clopidogrel Carboxylic Acid Discontinued See C587235
- SR 26334
- (S)-Clopidogrel Carboxylic Acid (Clopidogrel Related CoMpound A)
Thieno[3,2-c]pyridine-5(4H)-acetic acid, α-(2-chlorophenyl)-6,7-dihydro-, (αS)-
CAS:Formula:C15H14ClNO2SPurity:98%Color and Shape:SolidMolecular weight:307.7952Clopidogrel carboxylic acid
CAS:Clopidogrel Related Compound A is a useful organic compound for research related to life sciences.
Formula:C15H14ClNO2SColor and Shape:SolidMolecular weight:307.79Clopidogrel EP Impurity A ((S)-Clopidogrel Carboxylic Acid)
CAS:Formula:C15H14ClNO2SColor and Shape:Off-White SolidMolecular weight:307.79Clopidogrel carboxylic acid
CAS:Clopidogrel is a potent inhibitor of the platelet aggregation. It reduces blood clotting by inhibiting the ADP receptor on the surface of platelets, thereby inhibiting the aggregation and adhesion of platelets. Clopidogrel has been shown to be effective in preventing thrombosis, myocardial infarction (heart attack), and stroke. Clopidogrel inhibits the activity of cytochrome P450 3A4 (CYP3A4) and p2Y 12 receptors. Clopidogrel has been shown to have synergic effects with nonsteroidal anti-inflammatory drugs (NSAIDs). The polymorphic nature of Clopidogrel can be monitored using a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for quantification in biological samples such as human serum and plasma.
Formula:C15H14ClNO2SPurity:Min. 95%Molecular weight:307.8 g/mol




